{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:14:41Z","timestamp":1794960881553,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UC Cures","award":["BRD-16-501530"],"award-info":[{"award-number":["BRD-16-501530"]}]},{"name":"UC Cures","award":["BRD-16-501530"],"award-info":[{"award-number":["BRD-16-501530"]}]},{"name":"UC Cures","award":["BRD-16-501530"],"award-info":[{"award-number":["BRD-16-501530"]}]},{"name":"Alzheimer\u2019s Association Zenith Award .","award":["#1066394"],"award-info":[{"award-number":["#1066394"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Nicotinamide, a form of B3 vitamin, is an NAD\n                      <jats:sup>+<\/jats:sup>\n                      precursor that reduces pTau\n                      <jats:sub>231<\/jats:sub>\n                      levels via histone deacetylase inhibition in murine models of Alzheimer\u2019s disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of early AD. While nicotinamide demonstrated good safety and tolerability, it did not significantly lower CSF pTau\n                      <jats:sub>231<\/jats:sub>\n                      , the primary biomarker endpoint of the study. Characterization of nicotinamide\u2019s pharmacokinetics and metabolites in the blood and CSF is needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In these post hoc, blinded analyses of plasma and CSF samples from the completed two-site placebo controlled randomized trial testing of 1500\u00a0mg PO BID oral nicotinamide, we used mass spectroscopy to measure nicotinamide and its inactive metabolite 1-methyl-nicotinamide in plasma at baseline, 6, and 12\u00a0months and in CSF at baseline and 12\u00a0months from 23 participants on drug and 24 on placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pharmacokinetic analysis found mean 12\u00a0month plasma nicotinamide increased\u2009&gt;\u2009130-fold to 52\u00a0\u03bcM while mean methyl-nicotinamide increased\u2009&gt;\u2009600-fold to 91\u00a0\u03bcM in individuals receiving nicotinamide compared to those receiving placebo, whose levels were unchanged from baseline. However, CSF nicotinamide was only measurable in 6 of the 19 available participants (32%) (mean increase of at least 147-fold to 18\u00a0\u03bcM). These CSF nicotinamide concentrations were 66% of their plasma levels, indicating good CNS bioavailability in only some participants. In contrast to CSF nicotinamide, more treated participants had higher CSF methyl-nicotinamide (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099, 43\u00a0\u03bcM), suggesting high-dosage nicotinamide was sufficient to pass the blood\u2013brain barrier, but 13 of 19 were metabolically inactivated. Treatment favorably decreased mean pTau\n                      <jats:sub>231<\/jats:sub>\n                      levels by 34% in those six participants with elevated CSF levels of nicotinamide, compared to 3% elevation in participants who did not have elevated CSF nicotinamide, and a 3% decrease for placebo. No such relationships were observed for total tau, pTau\n                      <jats:sub>181<\/jats:sub>\n                      , or amyloid beta biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that oral administration markedly increased mean plasma nicotinamide levels, however CSF levels were below quantitation in a majority of participants and there was extensive metabolic inactivation to methyl-nicotinamide. Both the bioavailability and rapid metabolic methylation need to be addressed if nicotinamide is further developed as a potential intervention for AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      NCT03061474, last updated 2023\u201310-17.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03061474\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03061474<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01693-y","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:07:16Z","timestamp":1741666036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Gabriel L","family":"Ketron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Grun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","unstructured":"Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer\u2019s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28(45):11500\u201310. https:\/\/doi.org\/10.1523\/JNEUROSCI.3203-08.200810.1523\/JNEUROSCI.3203-08.2008.","DOI":"10.1523\/JNEUROSCI.3203-08.200810.1523\/JNEUROSCI.3203-08.2008"},{"issue":"6","key":"1693_CR2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2012.11.020","volume":"34","author":"D Liu","year":"2013","unstructured":"Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, Kawamoto EM, Mattson MP. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging. 2013;34(6):1564\u201380. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.11.020.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1693_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00971360","volume":"12","author":"R Spector","year":"1987","unstructured":"Spector R. Niacinamide transport through the blood-brain barrier. Neurochem Res. 1987;12(1):27\u201331. https:\/\/doi.org\/10.1007\/BF00971360.","journal-title":"Neurochem Res"},{"issue":"9","key":"1693_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/ars.2018.7722","volume":"31","author":"CA Kulkarni","year":"2019","unstructured":"Kulkarni CA, Brookes PS. Cellular Compartmentation and the Redox\/Nonredox Functions of NAD(). Antioxid Redox Signal. 2019;31(9):623\u201342. https:\/\/doi.org\/10.1089\/ars.2018.7722.","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"1693_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s42255-020-00305-3","volume":"2","author":"AJ Covarrubias","year":"2020","unstructured":"Covarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Heckenbach I, Kwok R, Wiley CD, et al. Senescent cells promote tissue NAD(+) decline during ageing via the activation of CD38(+) macrophages. Nat Metab. 2020;2(11):1265\u201383. https:\/\/doi.org\/10.1038\/s42255-020-00305-3.","journal-title":"Nat Metab"},{"key":"1693_CR6","unstructured":"Kohleimer, M. Nutrient Metabolism. Academic Press, 2003."},{"key":"1693_CR7","doi-asserted-by":"crossref","unstructured":"Grill JD. et al. Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease. Neurology 2025;104:e210152.","DOI":"10.1212\/WNL.0000000000210152"},{"key":"1693_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-981-32-9358-8_29","volume":"1184","author":"M Shoji","year":"2019","unstructured":"Shoji M. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. Adv Exp Med Biol. 2019;1184:393\u2013405. https:\/\/doi.org\/10.1007\/978-981-32-9358-8_29.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1693_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"1693_CR10","unstructured":"Armbruster, D A, Pry, T, Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29 Suppl 1 (Suppl 1): S49\u201352. From NLM PubMed-not-MEDLINE."},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tma.2021.09.001","volume":"5","author":"TK Ito","year":"2021","unstructured":"Ito TK, Tomohito S, Yusuke T, Zinat T, Takuya K, Keiichi O, Mitsutoshi S. A single oral supplementation of nicotinamide within the daily tolerable upper level increases blood NAD+ levels in healthy participants. Translational Medicine of Aging. 2021;5:43\u201351. https:\/\/doi.org\/10.1016\/j.tma.2021.09.001.","journal-title":"Translational Medicine of Aging"},{"issue":"2","key":"1693_CR12","doi-asserted-by":"publisher","first-page":"e5261","DOI":"10.1002\/bmc.5261","volume":"36","author":"J Chu","year":"2022","unstructured":"Chu J, Liu M, Dai G, Li C, Wu T, Zou J, Ju W, Xu M. Simultaneous determination of nicotinamide and N(1) -methylnicotinamide in human serum by LC-MS\/MS to associate their serum concentrations with obesity. Biomed Chromatogr. 2022;36(2):e5261. https:\/\/doi.org\/10.1002\/bmc.5261.","journal-title":"Biomed Chromatogr"},{"key":"1693_CR13","doi-asserted-by":"publisher","unstructured":"Ibrahim, G R, Shah, I, Gariballa, S, Yasin, J, Barker, J, Salman A, S. Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study. Molecules 2020;25 (17). https:\/\/doi.org\/10.3390\/molecules25173932","DOI":"10.3390\/molecules25173932"},{"issue":"2","key":"1693_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/rej.2018.2077","volume":"22","author":"J Clement","year":"2019","unstructured":"Clement J, Wong M, Poljak A, Sachdev P, Braidy N. The Plasma NAD(+) Metabolome Is Dysregulated in \u201cNormal\u201d Aging. Rejuvenation Res. 2019;22(2):121\u201330. https:\/\/doi.org\/10.1089\/rej.2018.2077.","journal-title":"Rejuvenation Res"},{"issue":"8","key":"1693_CR15","doi-asserted-by":"publisher","first-page":"e0201968","DOI":"10.1371\/journal.pone.0201968","volume":"13","author":"N Seyedsadjadi","year":"2018","unstructured":"Seyedsadjadi N, Berg J, Bilgin AA, Braidy N, Salonikas C, Grant R. High protein intake is associated with low plasma NAD+ levels in a healthy human cohort. PLoS ONE. 2018;13(8):e0201968. https:\/\/doi.org\/10.1371\/journal.pone.0201968.","journal-title":"PLoS ONE"},{"key":"1693_CR16","doi-asserted-by":"publisher","unstructured":"Galla, Z, Rajda, C, Racz, G, Grecso, N, Barath, A, Vecsei, L Bereczki, C, Monostori, P. Simultaneous determination of 30 neurologically and metabolically important molecules: A sensitive and selective way to measure tyrosine and tryptophan pathway metabolites and other biomarkers in human serum and cerebrospinal fluid. Journal of chromatography. A 2021;1635: 461775. https:\/\/doi.org\/10.1016\/j.chroma.2020.461775","DOI":"10.1016\/j.chroma.2020.461775"},{"issue":"3","key":"1693_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0009-8981(90)90322-j","volume":"186","author":"J Rini","year":"1990","unstructured":"Rini J, Szumlanski C, Guerciolini R, Weinshilboum RM. Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta. 1990;186(3):359\u201374. https:\/\/doi.org\/10.1016\/0009-8981(90)90322-j.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"1693_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s12035-020-02259-9","volume":"58","author":"A Kocinaj","year":"2021","unstructured":"Kocinaj A, Chaudhury T, Uddin MS, Junaid RR, Ramsden DB, Hondhamuni G, Klamt F, Parsons L, Parsons RB. High Expression of Nicotinamide N-Methyltransferase in Patients with Sporadic Alzheimer\u2019s Disease. Mol Neurobiol. 2021;58(4):1769\u201381. https:\/\/doi.org\/10.1007\/s12035-020-02259-9.","journal-title":"Mol Neurobiol"},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41419-022-04713-z","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang W, Yang C, Wang T, Deng H. Complex roles of nicotinamide N-methyltransferase in cancer progression. Cell Death Dis. 2022;13:267. https:\/\/doi.org\/10.1038\/s41419-022-04713-z.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1693_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00008571-199602000-00003","volume":"6","author":"T Scheller","year":"1996","unstructured":"Scheller T, Orgacka H, Szumlanski CL, Weinshilboum RM. Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains. Pharmacogenetics. 1996;6(1):43\u201353. https:\/\/doi.org\/10.1097\/00008571-199602000-00003.","journal-title":"Pharmacogenetics"},{"issue":"8","key":"1693_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm.3882","volume":"21","author":"S Hong","year":"2015","unstructured":"Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887\u201394. https:\/\/doi.org\/10.1038\/nm.3882.","journal-title":"Nat Med"},{"issue":"1","key":"1693_CR22","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1038\/s41598-018-22081-7","volume":"8","author":"A Kannt","year":"2018","unstructured":"Kannt A, Rajagopal S, Kadnur SV, Suresh J, Bhamidipati RK, Swaminathan S, Hallur MS, Kristam R, Elvert R, Czech J, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018;8(1):3660. https:\/\/doi.org\/10.1038\/s41598-018-22081-7.","journal-title":"Sci Rep"},{"issue":"1","key":"1693_CR23","doi-asserted-by":"publisher","first-page":"e13754","DOI":"10.1111\/acel.13754","volume":"22","author":"M Vreones","year":"2023","unstructured":"Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. https:\/\/doi.org\/10.1111\/acel.13754.","journal-title":"Aging Cell"},{"issue":"6","key":"1693_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.advnut.2023.08.008","volume":"14","author":"Q Song","year":"2023","unstructured":"Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023;14(6):1416\u201335. https:\/\/doi.org\/10.1016\/j.advnut.2023.08.008.","journal-title":"Adv Nutr"},{"issue":"7","key":"1693_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/nbm.3559","volume":"29","author":"M Lu","year":"2016","unstructured":"Lu M, Zhu XH, Chen W. In vivo (31) P MRS assessment of intracellular NAD metabolites and NAD(+) \/NADH redox state in human brain at 4 T. NMR Biomed. 2016;29(7):1010\u20137. https:\/\/doi.org\/10.1002\/nbm.3559.","journal-title":"NMR Biomed"},{"issue":"11","key":"1693_CR26","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.drudis.2021.05.011","volume":"26","author":"Y Gao","year":"2021","unstructured":"Gao Y, Martin NI, van Haren MJ. Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target. Drug Discov Today. 2021;26(11):2699\u2013706. https:\/\/doi.org\/10.1016\/j.drudis.2021.05.011.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1693_CR27","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/s41598-022-19634-2","volume":"12","author":"S Ruf","year":"2022","unstructured":"Ruf S, Rajagopal S, Kadnur SV, Hallur MS, Rani S, Kristam R, Swaminathan S, Zope BR, Gondrala PK, Swamy I, et al. Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2022;12(1):15440. https:\/\/doi.org\/10.1038\/s41598-022-19634-2.","journal-title":"Sci Rep"},{"issue":"40","key":"1693_CR28","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1021\/acs.biochem.8b00561","volume":"57","author":"S Hong","year":"2018","unstructured":"Hong S, Zhai B, Pissios P. Nicotinamide N-Methyltransferase Interacts with Enzymes of the Methionine Cycle and Regulates Methyl Donor Metabolism. Biochemistry. 2018;57(40):5775\u20139. https:\/\/doi.org\/10.1021\/acs.biochem.8b00561.","journal-title":"Biochemistry"},{"key":"1693_CR29","doi-asserted-by":"publisher","unstructured":"Kannt, A, Rajagopal, S, Hallur, M S, Swamy, I, Kristam, R, Dhakshinamoorthy, S, Czech, J, Zech, G, Schreuder, H, Ruf, S. Novel Inhibitors of Nicotinamide-N-Methyltransferase for the Treatment of Metabolic Disorders. Molecules 2021;26 (4). https:\/\/doi.org\/10.3390\/molecules26040991","DOI":"10.3390\/molecules26040991"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01693-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:40:41Z","timestamp":1741707641000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01693-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01693-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was waived. Access to participants blood and CSF samples were de-identified. Original participant consent to collect samples was approved by the UC Irvine Institutional Review Board (IRB) [\n                      \n                      ]. The trial was conducted in accordance with the International Council for Harmonization guidelines and the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for publication"}},{"value":"GLK, FG and GJB report no competing interests. JDG reports research support from NIA, Alzheimer\u2019s Association, BrightFocus Foundation, Eli Lilly, Genentech, Biogen, and Eisai. He received personal income for editorial service to Alzheimer\u2019s & Dementia. HHF reports grant funding from UC Cures BRD-16\u2013501530 with no personal funds received and all payments to the Alzheimer\u2019s Disease Cooperative Study at UC San Diego. HHF also discloses grant funding from Allyx Therapeutics, Biohaven Pharmaceuticals, Vivoryon (Probiodrug), and LuMind Foundation; service agreements for consulting activities with LuMind, Axon Neuroscience, Novo Nordisk, Arrowhead Pharmaceuticals, Roche\/Genentech Pharmaceuticals (DMC\/DSMB), Tau Consortium (SAB), Janssen Research & Development (DSMB), Biosplice Therapeutics; support for travel from Novo Nordisk, Royal Society of Canada, Translating Research in Elder Care (TREC), Association for Frontotemporal Dementia (AFTD), and Rainwater Charitable Foundation; and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. For these activities, no personal funds have been received with all payments to UC San Diego. HHF personally receives royalties for patent: Feldman HH (filed November 26, 2008). Detecting and Treating Dementia Serial Number 12\/3\u20132691 U.S. Patent No. PCT\/US2007\/07008. Washington, DC: U.S. Patent and Trademark Office. RAR has no relevant conflicts. He has research support from the National Institute on Aging, the Alzheimer\u2019s Association and is a consultant for Amydis Inc, Bioivt, Lexeo, Keystone Bio, Allyx, DiamiR, Ionis and PrecisionMed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}